Global Expansion Waterstone operates from Indianapolis with a manufacturing and R&D footprint in Wuhan, China, indicating a capacity for regional supply to Asia and North America. Sales opportunities exist in cross-border contract development and manufacturing (CDMO) services, API sourcing, and global supply partnerships.

FDA cGMP Readiness The company has established facilities compliant with ICH Q7 and US FDA cGMP since 2010, signaling a credible path for customers seeking established quality and regulatory alignment for APIs and advanced starting materials.

Diverse Catalog With a catalog of over 30,000 research products and offerings in custom synthesis, development, and manufacturing, there are multiple entry points for selling raw materials, intermediates, and tailored production services to biotech and pharma clients.

Funding Momentum A Series C financing of approximately $61 million plus current revenue suggests growing capacity and investment in tech and manufacturing capabilities, creating opportunities to upsell scale-up programs, new API lines, and enhanced CDMO collaborations.

Tech-Driven Capabilities Existing tech stack and digital presence imply potential for digital sales enablement, online product procurement, and streamlined customer onboarding for API and custom manufacturing projects, appealing to procurement teams seeking efficiency.